Healthtech startup Bonatra made a game-changing move earlier this month by acquiring women’s health and wellness startup MyAva.
Bonatra’s holistic healthcare programs for chronic conditions, when combined with MyAva’s curated plans for PCOS, thyroid disorders and insulin resistance, place them in a good spot to make strides in the Indian market.
With Bonatra’s doctor-led team and expertise in IoT devices, the merger promises ground-breaking solutions for chronic disease management. While details of the deal aren’t completely disclosed, Rahul Kishore Singh, Bonatra’s CEO, says this acquisition is a strategic fit for the company’s goals.
Let’s understand both the startups and how the acquisition can help women.
Bonatra acquires MyAva: How will the acquisition help women?
Bonatra is a chronic disease management startup focusing on treating and managing conditions like diabetes, hypertension, fatty liver, PCOS and obesity with a doctor-led approach. MyAva is a femtech startup focusing on PCOS, thyroid disorders and insulin resistance in women with personalised treatment.
Bonatra’s acquisition of MyAva is a strategic move fuelled by the synergy between both startups. MyAva’s user base consists of women managing chronic conditions, which perfectly aligns with Bonatra’s emphasis on chronic disease management.
The acquisition will broaden Bonatra’s scope and knowledge in women’s health while furthering its goal to become the go-to solution for managing chronic health issues. The excitement surrounding the acquisition is mutual, as MyAva shares Bonatra’s commitment to making chronic care accessible to all women.
By joining forces, they will provide a comprehensive and holistic approach to women’s health, empowering them to take proactive measures against chronic conditions.
Bonatra plans to launch its smart ring in six months to enhance its medical and data-driven solutions. Its ambitious growth plans and innovative devices will solidify Bonatra’s market position and advance its vision of accessible chronic care management.
About Bonatra
Bonatra is an Indian chronic disease management startup founded in April 2022 by Rahul Kishore Singh, Manjari Chandra, Ramanpreet Singh and Amit Acharya.
Using a doctor-led approach, it leverages the Internet of Medical Things (IoMT) devices to analyse various health parameters and data points. This enables Bonatra to create tailored treatment plans, integrating clinical acumen with technology.
Bonatra’s solutions include personalised lifestyle modifications, targeted nutritional interventions and fitness programs to balance hormones. It also addresses gut dysbiosis (imbalance in gut bacteria) and utilises natural detox procedures to reduce heavy metal toxicity in the body.
Through its innovative approach and commitment to holistic health, Bonatra is transforming how chronic diseases are managed.
About MyAva
MyAva is an Indian femtech startup founded in 2019 by Evelyn Immanuel. It empowers women to manage chronic health conditions by offering curated programs and personalised plans tailored to individual needs.
Through their innovative approach to women’s health and wellness, MyAva provides women with the tools and resources to take control of their health and improve their well-being.
Market outlook for Bonatra
Amidst the thriving health-tech industry, Bonatra’s acquisition of MyAva aligns perfectly with the growing demand for comprehensive healthcare solutions. The Covid-19 pandemic has propelled the Indian health-tech market, which is projected to reach a staggering $21 billion by 2025.
Last year, Bonatra secured INR 5.5 crore in the pre-seed funding round, attracting investments from renowned angel investors Jitendra Jagadev and Rajesh Yabaji.
Building on this momentum, Bonatra plans to introduce new IoMT devices to enhance its cutting-edge solutions, integrating medical science, data science and technology.
While the industry continues to flourish, some health-tech startups have experienced setbacks due to the ongoing funding winter and economic turbulence. Practo, Innovaccer and Phablecare have made difficult decisions to lay off employees.
Nevertheless, Bonatra’s strategic move solidifies its position in the dynamic health-tech landscape and positions it as a frontrunner in meeting the evolving healthcare demands of today’s digital era.
